Can Kamada (KMDA) Stock Reach $14?

Kamada Ltd. (KMDA) is an Israeli biopharmaceutical company that develops and sells plasma-derived protein therapeutics for rare and serious conditions, including KEDRAB (rabies immunoglobulin), Varizig, and HepaGam. Its shares trade on Nasdaq, and investors have been weighing whether a run toward the $14 level is realistic.

Key Takeaways

• The central target used here is $14, representing the arithmetic mean of four current analyst price targets rounded from $13.75.
• The four reviewed targets span a wide range of $12 to $15, reflecting meaningful disagreement about the stock's near-term upside.
• At a recent price near $7.72, reaching $14 would require a gain of roughly 81% — a very large move relative to the stock's trading range.
• Supporting factors include record nine-month revenue, rising margins, a strong cash position, and a unanimous Buy rating from covering analysts.
• The biggest risks are the stock's low trading volume, its large gap to prior highs, and valuation that depends on sustained earnings growth.
• For more detail, explore the stock's Major News, Today's Price Move, Forecast, and Earnings pages.
• To see AI-driven trading strategies applied across the market, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Four current analyst price targets were reviewed for this analysis. The arithmetic mean is $13.75, which rounds to a $14 central target, with an approximate range of $12 to $15.

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating and raised the target from $11 to $12 in early November 2026. H.C. Wainwright's Andrew Fein maintained a Buy and a $13 target in September 2026, after raising it from $11 late in 2025. Benchmark's Robert Wasserman has repeatedly maintained a Buy with a $15 target, and William Blair set a $15 price objective in mid-2026.

The spread between $12 and $15 is notable. The higher targets from Benchmark and William Blair appear to reflect confidence in Kamada's plasma-therapy franchise and improving profitability, while the more conservative figures from Stifel and H.C. Wainwright suggest caution about the speed of a re-rating. All four analysts rate the stock a Buy, so the disagreement is about magnitude, not direction. This mean is a calculation, not an official published consensus, and should not be read as a guarantee.

Current Market Position and Path Toward the Target

As of early November 2026, KMDA traded near $7.72, with a market capitalization of roughly $444 million and a trailing P/E (price-to-earnings) ratio near 20. The stock's 52-week range is approximately $6.60 to $9.35, meaning the shares sit in the lower-middle portion of their recent range.

Reaching $14 would require an upside of roughly 81% from $7.72 — a very large move that would take the stock roughly 50% above its 52-week high of $9.35. Such a path would likely depend on a combination of sustained double-digit revenue growth, continued margin expansion, and a broader re-rating of the shares by institutional investors, rather than any single catalyst.

What Could Support a Move Toward the Target

Kamada reported record nine-month revenue of $152.2 million for 2026, up 12% year over year, with third-quarter revenue of $52 million, up 11%. Net income for the quarter rose 51% to $8 million, or $0.14 per diluted share, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 30% to $15.2 million. The company held about $75.3 million in cash and short-term investments at the end of September 2026 and continues to pay a cash dividend, underscoring its ability to convert profit into cash flow.

Growth is being driven by demand for KEDRAB, Varizig, and HepaGam, along with a distribution segment that grew 35% in the quarter. A supply agreement with Kedrion running through 2031 and the company's vertical integration into plasma collection support a multi-year demand outlook. Analysts' unanimous Buy ratings reflect confidence that this fundamental momentum can justify a higher valuation.

What Could Prevent the Target From Being Reached

The principal obstacle is scale. A move from $7.72 to $14 is not a small step for a company with a market value below $500 million and relatively modest trading volume, which can amplify volatility. The target also sits far above the stock's 52-week high, meaning the market has not yet validated a sustained move beyond $9.35.

Other risks include competition in plasma-derived therapies, reliance on a concentrated product portfolio, foreign-exchange exposure given the company's Israel-based operations, and the possibility that earnings growth slows or margins compress. A broader rotation away from small-cap or healthcare names, or any setback in commercial execution, could also keep the shares range-bound.

Technical Levels and Market Structure

The stock's 52-week high near $9.35 represents a meaningful resistance level that the shares would first need to reclaim and hold. The $6.60 area marks the lower end of the recent range and serves as a support level. The $14 target sits well above both, implying that a durable breakout beyond prior highs would be a prerequisite for the move analysts envision.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ. Investors should watch quarterly earnings and revenue growth, gross-margin trends, any updates to full-year guidance, dividend declarations, and changes to analyst targets. Developments in the KEDRAB franchise, the Kedrion partnership, and plasma-collection capacity are also key, as are broader small-cap and healthcare sector flows.

AI Daily Buy/Sell Signals

Traders looking to time entries and exits around KMDA can use Tickeron's AI Daily Buy/Sell Signals. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. Consider pairing these signals with the fundamental and technical context above when evaluating KMDA.

Final Assessment

The $14 central target reflects the average of four current analyst price targets, rounded from $13.75, against a range of $12 to $15. From a recent price near $7.72, that implies a very large required move of about 81%. The bull case rests on record revenue, expanding margins, a strong balance sheet, and a unanimous Buy rating, while the bear case centers on the stock's small size, modest liquidity, and a target far above its 52-week high. Whether KMDA approaches $14 will likely depend on sustained earnings momentum and a genuine re-rating by investors — neither of which is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations